Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve

Abstract Aim We analyzed the association between the modified albumin–bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u‐HCC). Methods In this retrospective observational study, we included 71 u‐...

Cijeli opis

Bibliografski detalji

Glavni autori:	Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Morishita Asahiro, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Tsutomu Masaki, Tetsuji Takayama
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2023-02-01
Serija:	Cancer Medicine
Teme:	atezolizumab bevacizumab hepatocellular carcinoma
Online pristup:	https://doi.org/10.1002/cam4.5145
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!